Anne Applebaum tells Stephanie Ruhle she believes Elon Musk is attempting to change our government to one where civil servants are responsible to the leader of the ruling party.

Star Wars fans who grew up with the Original Trilogy had every reason to think that the Jedi were very … Continue reading ...

The Akron men's basketball team is "trending in the right direction" atop the Mid-American Conference with scorers Nate Johnson and Tavari Johnson.

Reviewers have tested some of the products below and may have received some products from the manufacturers for free. All opinions are the reviewers’ own. These full-spectrum gummies are ...

OKC Thunder superstar Shai Gilgeous-Alexander scored a career-high 54 points in a 123-114 win over the Utah Jazz on Wednesday night.

Class of 2025 quarterback Au'Tori Newkirk has committed to North Carolina, he told ESPN on Tuesday, continuing coach Bill Belichick's offseason rebuild of the Tar Heels' quarterback room.

Many experts say the new Trump administration could be more strategic and wise this time. That revving you hear from Sacramento is the sound of California’s Democratic leaders preparing to sue the tar ...

Your sneakers are one of the most important items in your closet. Whether you’re on your feet a lot for your job, rack up the miles during long runs, play a club sport, or are a regular at your local ...

In my fridge door, you’ll always find a trusty mason jar of pickled red onions tucked alongside the dijon mustard, mayo, tamari, and (too many) hot sauces. For me, pickled onions reign above any other ...

Raritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients ...

Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with bladder cancer.

Johnson & Johnson seeks FDA approval for TAR-200, targeting BCG-unresponsive high-risk NMIBC with CIS, through the Real-Time Oncology Review program. Phase 2b SunRISe-1 trial data showed an 83.5% ...